Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01919437
Other study ID # 2011.118-2
Secondary ID
Status Active, not recruiting
Phase N/A
First received May 29, 2013
Last updated August 7, 2013
Start date April 2012
Est. completion date October 2013

Study information

Verified date August 2013
Source California Pacific Medical Center Research Institute
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to develop the technology infrastructure for a mobile Web-based cognitive and neuropsychological assessment of substance abusers, and to perform a pilot trial using neurocognitive tasks designed to demonstrate that our system is statistically comparable to current clinical practice.

The primary hypotheses are that results collected using a web-based data collection platform will be comparable (but not necessarily equivalent) to data collected under controlled laboratory conditions, that methamphetamine (MA) dependent participants will have worsened neurocognitive performance compared to healthy volunteers, and the platform will be acceptable to participants.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 32
Est. completion date October 2013
Est. primary completion date October 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Male or female, aged 18 to 55.

- Ability to give informed consent.

Exclusion Criteria:

- Unwilling or unable to access the web over a cell phone or living in an area with no cell phone service.

- Any medical, psychiatric, or other condition that, in the opinion of the investigator, would preclude safe, consistent, or useful participation in the study.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Device:
Web-Enabled Cognitive Neuropsychological Evaluation System


Locations

Country Name City State
United States CPMC Addiction & Pharmacology Research Laboratory San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
California Pacific Medical Center Research Institute Creare, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of neurocognitive task results Results collected using a web-based data collection platform will be comparable (but not necessarily equivalent) to data collected under controlled laboratory conditions. 2 weeks No
See also
  Status Clinical Trial Phase
Terminated NCT01813656 - An Study of Aripiprazole in the Treatment of Methamphetamine Dependence Phase 4
Completed NCT00984360 - Study of Naltrexone for Methamphetamine Addiction Phase 2
Completed NCT01685463 - Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving N/A
Completed NCT00569374 - Safety and Tolerability of Modafinil for Methamphetamine Dependence Phase 2
Completed NCT01967381 - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse Early Phase 1
Completed NCT01354470 - A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence Phase 2
Active, not recruiting NCT01044238 - Methylphenidate to Treat Methamphetamine Dependence Phase 2
Completed NCT01215929 - Studying Amphetamine Withdrawal in Humans Phase 2
Terminated NCT01019707 - Safety Assessment of Atomoxetine With MA IV Administration Phase 1
Completed NCT00227123 - A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence N/A
Recruiting NCT02568878 - Creatine for Depressed Male and Female Methamphetamine Users Phase 3
Completed NCT01007539 - Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence Phase 3
Completed NCT01011829 - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence Phase 2
Completed NCT01062451 - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence Phase 1
Completed NCT00687713 - Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence Phase 2
Completed NCT01063205 - NAC as a Potential Treatment for Methamphetamine Dependence Phase 1
Completed NCT02058966 - Pilot Study of Entacapone for Methamphetamine Abuse Early Phase 1
Completed NCT00332605 - N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence Phase 2
Completed NCT01860807 - Trial of Ibudilast for Methamphetamine Dependence Phase 2
Terminated NCT01813643 - A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis Phase 4